Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
Authors
Keywords
-
Journal
RMD Open
Volume 9, Issue 1, Pages e002676
Publisher
BMJ
Online
2023-03-01
DOI
10.1136/rmdopen-2022-002676
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Physical function and physical activity in adults with X-linked hypophosphatemia
- (2022) G. Orlando et al. OSTEOPOROSIS INTERNATIONAL
- Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
- (2022) Thomas J Weber et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
- (2021) Karine Briot et al. RMD Open
- Musculoskeletal Features in Adults With X-linked Hypophosphatemia: An Analysis of Clinical Trial and Survey Data
- (2021) Muhammad Kassim Javaid et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hyperparathyroidism in patients with X‐linked hypophosphatemia
- (2020) Anne‐Lise Lecoq et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study
- (2020) S. H. Lo et al. QUALITY OF LIFE RESEARCH
- PRO80 PSYCHOMETRIC VALIDATION OF THE BRIEF FATIGUE INVENTORY (BFI) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)
- (2020) A. Nixon et al. VALUE IN HEALTH
- FGF23 and its role in X-linked hypophosphatemia-related morbidity
- (2019) Signe Sparre Beck-Nielsen et al. Orphanet Journal of Rare Diseases
- Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
- (2019) Dieter Haffner et al. Nature Reviews Nephrology
- Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
- (2019) Anthony A. Portale et al. CALCIFIED TISSUE INTERNATIONAL
- PRO154 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE BRIEF PAIN INVENTORY (BPI-SF) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)
- (2019) A. Skrinar et al. VALUE IN HEALTH
- PRO152 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE WESTERN ONTARIO MCMASTER UNIVERSITIES OSTEOARTHRITIS INVENTORY (WOMAC) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)
- (2019) A. Skrinar et al. VALUE IN HEALTH
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis
- (2018) Karl L Insogna et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations
- (2018) Douglas Chesher et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Qualitative Research to Explore the Patient Experience of X-Linked Hypophosphatemia and Evaluate the Suitability of the BPI-SF and WOMAC® as Clinical Trial End Points
- (2018) Christina Theodore-Oklota et al. VALUE IN HEALTH
- Exploring the Link between Serum Phosphate Levels and Low Muscle Strength, Dynapenia, and Sarcopenia
- (2018) Yuan-Yuei Chen et al. Scientific Reports
- Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms
- (2016) Hélène Che et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Abnormalities in Muscle Density and Muscle Function in Hypophosphatemic Rickets
- (2012) Louis-Nicolas Veilleux et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A clinician's guide to X-linked hypophosphatemia
- (2011) Thomas O Carpenter et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Population-Based Normative Values for the Western Ontario and McMaster (WOMAC) Osteoarthritis Index: Part I
- (2011) Nicholas Bellamy et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started